Drug Trial Radar · NCT05092386
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Jan 3, 2023
Primary completion
May 26, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 weeks, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial of the a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to preliminary evaluate the safety and immunogenicity of the study vaccine
Conditions
- Pneumococcal Infections
Interventions
Investigational 13-valent Pneumococcal Polysaccharide Conjugate VaccineBiological
The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)Biological
The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)Biological
The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety index-incidence of adverse reactionsTime frame: Day 0-30 after each dose of experimental vaccine
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.